Login to Your Account

PPD Buying $25M Of Syrrx Stock As Part Of Diabetes Collaboration

By Aaron Lorenzo

Friday, November 21, 2003
PPD Inc. is taking a stake in privately held Syrrx Inc. as part of a drug development deal. The companies agreed to partner their resources in further developing Syrrx-designed human dipeptidyl peptidase-IV (DP4) inhibitors for Type II diabetes and other diseases. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription